<DOC>
	<DOCNO>NCT00003159</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know surgery effective without preoperative chemotherapy treat non-small cell lung cancer . PURPOSE : This randomized phase III trial study surgery preoperative chemotherapy see well work compare surgery alone treat patient resectable non-small cell lung cancer .</brief_summary>
	<brief_title>Surgery With Without Preoperative Chemotherapy Treating Patients With Resectable Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare survival patient resectable non-small cell lung cancer treat surgery without preoperative chemotherapy . Secondary - Compare quality life patient treat regimen . - Compare pre-randomization clinical post-surgical pathological staging patient treat regimen . - Compare resectability rate patient treat regimen . - Compare time site relapse patient treat regimen . - Determine response patient treat preoperative chemotherapy . - Determine adverse effect preoperative chemotherapy patient . OUTLINE : This randomize study . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo surgical resection 4 week randomization . - Arm II : Patients receive one follow chemotherapy regimen immediately randomization : - Regimen 1 : Patients receive mitomycin IV , vinblastine IV , cisplatin IV day 1 . - Regimen 2 : Patients receive mitomycin IV , ifosfamide IV 3 hour , cisplatin IV 1 hour day 1 . - Regimen 3 : Patients receive cisplatin IV 2 hour day 1 vinorelbine IV 5 -10 minute day 1 8 . - Regimen 4 : Patients receive paclitaxel IV carboplatin IV day 1 . - Regimen 5 : Patients receive gemcitabine IV day 1 8 cisplatin IV 2 hour day 1 . - Regimen 6 : Patients receive docetaxel IV carboplatin IV day 1 . In regimen , treatment repeat every 3 week total 3 course . Patients undergo surgical resection least 4 week last course chemotherapy . Quality life assess 6 12 month annually thereafter . Patients follow 1 month surgery , 6 month randomization , every 3 month 2 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 600 patient ( 300 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove nonsmall cell lung cancer Resectable disease Previously untreated disease No evidence distant metastases PATIENT CHARACTERISTICS : Age : Any age Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm^3 Neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Not specify Renal : Not specify Other : Considered fit chemotherapy surgical resection No disease prior malignancy would preclude study treatment No active infection PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent prophylactic colonystimulating factor ( except secondary prophylaxis ) No concurrent immunotherapy Chemotherapy : Not specify Endocrine therapy : No concurrent hormonal agent , except corticosteroid Radiotherapy : Not specify Surgery : Not specify Other : No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage 0 non-small cell lung cancer</keyword>
</DOC>